|

A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

RECRUITINGPhase 2Sponsored by Alnylam Pharmaceuticals
Actively Recruiting
PhasePhase 2
SponsorAlnylam Pharmaceuticals
Started2026-01-15
Est. completion2027-05-28
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07465224

Summary

The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

* Is an adult patient with a confirmed diagnosis of T2DM
* Has a body mass index (BMI) of ≥25 kg/m\^2 and \<39.9 kg/m\^2
* Has a hemoglobin A1c (HbA1c) ≥6.5% to \<10.5%
* Is on a stable dose of metformin

Exclusion Criteria:

* Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
* Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods

Note: other protocol defined inclusion/exclusion criteria apply

Conditions2

DiabetesType 2 Diabetes Mellitus (T2DM)

Interventions1

ALN-4324

Locations1 site

Clinical Trial Site
Chula Vista, California, 91911

Find trials near these locations

All trials in California

Related trials

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.